<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" open-status="O" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue journalpublishing.dtd?><?DTDIdentifier.IdentifierType system?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Mol Vis</journal-id><journal-id journal-id-type="publisher-id">MV</journal-id><journal-title-group><journal-title>Molecular Vision</journal-title></journal-title-group><issn pub-type="epub">1090-0535</issn><publisher><publisher-name>Molecular Vision</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">3265175</article-id><article-id pub-id-type="publisher-id">15</article-id><article-id pub-id-type="publisher-id">2011MOLVIS0473</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="8699" pm="."><plain>The association of CD36 variants with polypoidal choroidal vasculopathy compared to typical neovascular age-related macular degeneration </article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Bessho</surname><given-names>Hiroaki</given-names></name></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Honda</surname><given-names>Shigeru</given-names></name></contrib><contrib contrib-type="author"><name><surname>Kondo</surname><given-names>Naoshi</given-names></name></contrib><contrib contrib-type="author"><name><surname>Kusuhara</surname><given-names>Sentaro</given-names></name></contrib><contrib contrib-type="author"><name><surname>Tsukahara</surname><given-names>Yasutomo</given-names></name></contrib><contrib contrib-type="author"><name><surname>Negi</surname><given-names>Akira</given-names></name></contrib><aff id="aff1">Department of Surgery, Division of Ophthalmology, Kobe University Graduate School of Medicine, Chuo-ku, Kobe, Japan</aff></contrib-group><author-notes><corresp id="cor1">Correspondence to: Shigeru Honda, Department of Surgery, Division of Ophthalmology, Kobe University Graduate School of Medicine, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan; Phone: +81-78-382-6048; FAX: +81-78-382-6059; email: <email xlink:href="sighonda@med.kobe-u.ac.jp">sighonda@med.kobe-u.ac.jp</email></corresp></author-notes><pub-date pub-type="collection"><year>2012</year></pub-date><pub-date pub-type="epub"><day>18</day><month>1</month><year>2012</year></pub-date><volume>18</volume><fpage>121</fpage><lpage>127</lpage><history><date date-type="received"><day>19</day><month>10</month><year>2011</year></date><date date-type="accepted"><day>12</day><month>1</month><year>2012</year></date></history><permissions><copyright-statement>Copyright © 2012 Molecular Vision.</copyright-statement><copyright-year>2012</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0/"><license-p>This is an open-access article distributed under the terms of the        Creative Commons Attribution License, which permits unrestricted use,
        distribution, and reproduction in any medium, provided the original
        work is properly cited.</license-p></license></permissions><abstract><sec><title><text><SENT sid="8700" pm="."><plain>Purpose <p><SecTag type="ABS"><text><SENT sid="8701" pm="."><plain>To clarify the association of cluster of differentiation 36 (CD36) variants with polypoidal choroidal vasculopathy (PCV) and compare them with those in typical neovascular age-related macular degeneration (tAMD). </p></sec><sec><title><text><SENT sid="8702" pm="."><plain>Methods <p><SecTag type="ABS"><text><SENT sid="8703" pm="."><plain>We included 349 Japanese AMD patients (210 PCV, 139 tAMD) and 198 age-matched controls. Four tag single-nucleotide polymorphisms (SNPs)—rs10499862, rs3173798, rs3211883, and rs3173800—in the CD36 region were genotyped using the TaqMan assay. Allelic and genotypic frequencies of the SNPs were tested. </p></sec><sec><title><text><SENT sid="8706" pm="."><plain>Results <p><SecTag type="ABS"><text><SENT sid="8707" pm="."><plain>Although none of the SNPs tested were associated with PCV, the allelic frequencies of rs3173798 and rs3173800 were significantly different between PCV and tAMD patients. Genotype association analysis demonstrated different associations of these two SNPs between PCV and tAMD in the genotype model. Haplotype analysis revealed that the association of the major haplotype (T-T-T-T) at four selected SNPs in CD36 differed significantly between PCV and tAMD patients. </p></sec><sec><title><text><SENT sid="8710" pm="."><plain>Conclusions <p><SecTag type="ABS"><text><SENT sid="8711" pm="."><plain>The CD36 region may be associated with the difference in genetic susceptibility for PCV and tAMD. </p></sec></abstract><custom-meta-group><custom-meta><meta-name>GalleyStatus</meta-name><meta-value>Export to XML</meta-value></custom-meta><custom-meta><meta-name>corr-author</meta-name><meta-value>Honda</meta-value></custom-meta></custom-meta-group></article-meta></front><body><SecTag type="INTRO"><sec><title><text><SENT sid="8712" pm="."><plain>Introduction <p><text><SENT sid="8713" pm="."><plain>Age-related macular degeneration (AMD) is a leading cause of central vision loss in the elderly in industrialized countries [1]. </plain></SENT>
<SENT sid="8714" pm="."><plain>Although the number of patients with AMD has increased remarkably over the years, the pathology of AMD is not well understood [2]. </plain></SENT>
<SENT sid="8715" pm="."><plain>Advanced AMD is clinically classified into atrophic AMD and exudative AMD. In exudative AMD, there are two characteristic phenotypes distinct from typical neovascular AMD (tAMD), which are called polypoidal choroidal vasculopathy (PCV) [3,4] and retinal angiomatous proliferation [5]. </plain></SENT>
<SENT sid="8717" pm="."><plain>These two phenotypes are known to have different aspects from tAMD in their natural courses, as well as different responses to interventions such as photodynamic therapy (PDT) and anti–vascular endothelial growth factor therapy, although the reasons for this remain unknown [6-10]. </plain></SENT>
<SENT sid="8718" pm="."><plain>Recently, several genetic association studies have been conducted to explain the different characteristics among the phenotypes of exudative AMD and their susceptibility to several interventions, mainly PDT [11-19]. <p><text><SENT sid="8719" pm="."><plain>Cluster of differentiation 36 (CD36) is a multifunctional molecule that plays an important role in lipid metabolism, angiogenesis, inflammation, and scavenging oxidative stresses [20-22], all of which may be involved in the pathogenesis of AMD and in the mechanism whereby PDT functions. We previously demonstrated the association of coding variants in the CD36 region with the incidence of neovascular AMD (corresponding to tAMD in the present report) in the Japanese population [23]. </plain></SENT>
<SENT sid="8721" pm="."><plain>In that study, two variants of single nucleotide polymorphisms (SNPs)—<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=3173798">rs3173798</ext-link> and <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=3211883">rs3211883</ext-link> on introns 3 and 4, which have high linkage disequilibrium—showed the greatest association with susceptibility to neovascular AMD. However, it has not been determined whether this association is general to all exudative AMD or specific for tAMD. We hypothesized that the genetic variants in CD36 may be differently associated with genetic susceptibilities to tAMD and PCV. Since PCV is known to have a better response to PDT than tAMD [7,8], we considered that the scavenging ability of CD36 for reactive oxygen species generated by PDT might be different between tAMD and PCV, which could influence the effect of PDT. <p><text><SENT sid="8725" pm="."><plain>We previously reported that coding variants of the elastin gene (ELN) were associated with PCV but not with tAMD [13]. </plain></SENT>
<SENT sid="8726" pm="."><plain>However, two recent reports with larger cohorts showed the opposite results: The ELN polymorphism was associated with tAMD but not with PCV [24,25]. </plain></SENT>
<SENT sid="8727" pm="."><plain>Although the association of elastin gene variants with tAMD and PCV is still inconclusive, these results might have been generated due to statistical type 1 and type 2 errors. In the present study, we included a sufficient number of subjects based on power analysis to prevent these errors. <p><text><SENT sid="8729" pm="."><plain>In this study, we genotyped four tag SNPs located on introns 3 and 4 of the CD36 gene, and analyzed the association between these variants and the incidence of PCV, as well as tAMD, in a Japanese population. </sec></SecTag><SecTag type="METHODS"><sec sec-type="methods"><title><text><SENT sid="8730" pm="."><plain>Methods <sec><title><text><SENT sid="8731" pm="."><plain>Study participants <p><text><SENT sid="8732" pm="."><plain>This is an extension study of a previous report [23]. </plain></SENT>
<SENT sid="8733" pm="."><plain>The study was approved by the Institutional Review Board of the Kobe University Graduate School of Medicine, and was conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from all subjects. All cases in this study were Japanese individuals recruited from the Department of Ophthalmology at Kobe University Hospital in Japan. <p><text><SENT sid="8736" pm="."><plain>The study included 349 Japanese AMD patients (210 PCV, 139 tAMD) and 198 age-matched controls who accepted DNA sampling. The tAMD group in this study included the patients of our previous study, along with 30 new patients. The control group in this study included the subjects of the previous study and 16 more individuals [23]. </plain></SENT>
<SENT sid="8739" pm="."><plain>All patients received ophthalmic examinations, including visual acuity measurements with refractive correction, slit-lamp biomicroscopy of the fundi, color fundus photographs, optical coherence tomography, fluorescein angiography, and indocyanine green angiography (ICGA). </plain></SENT>
<SENT sid="8740" pm="."><plain>All PCV subjects enrolled in this study met the criteria of definite cases of PCV as proposed by the Japanese Study Group of Polypoidal Choroidal Vasculopathy [26]. </plain></SENT>
<SENT sid="8741" pm="."><plain>ICGA showed a choroidal origin of the polypoidal lesions in all PCV cases, typically with vascular networks in the posterior poles and subretinal reddish-orange protrusions corresponding to the polypoidal lesions on ICGA. In contrast, all tAMD patients had clear images of choroidal neovascular networks on ICGA. The classification of the AMD phenotype was performed by three independent retinal specialists for each case under masked conditions for the genotype. Only those cases whose diagnoses were matched by all three readers were included in this study. The details of the participants are listed in Table 1. <SecTag type="TABLE"><table-wrap id="t1" position="float"><label>Table 1</label><caption><title><text><SENT sid="8746" pm="."><plain>Data summary of PCV and tAMD patients and control subjects. </caption><table frame="hsides" rules="groups"><col width="149" span="1"/><col width="87" span="1"/><col width="80" span="1"/><col width="85" span="1"/><thead><tr><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><text><SENT sid="8747" pm="."><plain>Factors </plain></SENT>
</text></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><text><SENT sid="8748" pm="."><plain>PCV </plain></SENT>
</text></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><text><SENT sid="8749" pm="."><plain>tAMD </plain></SENT>
</text></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><text><SENT sid="8750" pm="."><plain>Control </plain></SENT>
</text></th></tr></thead><tbody><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1"><text><SENT sid="8751" pm="."><plain>Number of subjects </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8752" pm="."><plain>210 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8753" pm="."><plain>139 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8754" pm="."><plain>198 </plain></SENT>
</text></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1"><text><SENT sid="8755" pm="."><plain>Gender (male/female) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8756" pm="."><plain>166/44 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8757" pm="."><plain>108/31 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8758" pm="."><plain>119/79 </plain></SENT>
</text></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1"><text><SENT sid="8759" pm="."><plain>Mean age±SD (years) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8760" pm="."><plain>73.8±7.5 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8761" pm="."><plain>75.3±7.3 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8762" pm="."><plain>72.1±5.9 </plain></SENT>
</text></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1"><text><SENT sid="8763" pm="."><plain>Median age (years) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8764" pm="."><plain>75 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8765" pm="."><plain>76 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8766" pm="."><plain>72 </plain></SENT>
</text></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1"><text><SENT sid="8767" pm="."><plain>Age range (years) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8768" pm="."><plain>51–93 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8769" pm="."><plain>55–94 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8770" pm="."><plain>56–95 </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><p><text><SENT sid="8771" pm="."><plain>PCV: polypoidal choroidal vasculopathy, tAMD: typical neovascular AMD. </table-wrap-foot></table-wrap></SecTag></sec><sec><title><text><SENT sid="8772" pm="."><plain>Single-nucleotide polymorphism selection <p><text><SENT sid="8773" pm="."><plain>The four tag SNPs—<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=10499862">rs10499862</ext-link>, <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=3173798">rs3173798</ext-link>, <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=3211883">rs3211883</ext-link>, and <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=3173800">rs3173800</ext-link> on introns 3 and 4 in the CD36 region—were selected based on our previous study [23], including SNPs which were significantly associated with tAMD (allelic nominal p-values &lt;0.01). </plain></SENT>
<SENT sid="8774" pm="."><plain>These four SNPs were in a single haplotype block using the algorithm based on the solid spine of linkage disequilibrium. </sec><sec><title><text><SENT sid="8775" pm="."><plain>Genotyping <p><text><SENT sid="8776" pm="."><plain>Genomic DNA was extracted from the peripheral blood using the <ext-link ext-link-type="uri" xlink:href="http://www.qiagen.com/Products/GenomicDnaStabilizationPurification/QIAampSystem/QIAampDNABloodMaxiKit.aspx?pf=1">QIAamp DNA Blood Maxi Kit </ext-link>(Qiagen, Valencia, CA). </plain></SENT>
<SENT sid="8777" pm="."><plain>Genotyping was performed using TaqMan® SNP Genotyping Assays or Custom TaqMan® SNP Genotyping Assays (Applied Biosystems, Foster City, CA) on a StepOnePlus™ Real-Time PCR System (Applied Biosystems) in accordance with the supplier’s recommendations. </sec><sec><title><text><SENT sid="8778" pm="."><plain>Statistical analysis <p><text><SENT sid="8779" pm="."><plain>All SNPs were evaluated for Hardy–Weinberg equilibrium using the χ2 test (one degree of freedom) with SNPAlyze version 7.0.1 (DYNACOM, Yokohama, Japan). </plain></SENT>
<SENT sid="8780" pm="."><plain>The allelic and genotype frequency distributions were compared among tAMD, PCV, and control subjects using a χ2 test with one or two degrees of freedom for the allelic and genotypic tests, respectively. To avoid false-positive results, the Bonferroni or permutation correction was added for each comparison. P values &lt;0.05 were considered to be statistically significant. <p><text><SENT sid="8783" pm="."><plain>To exclude a potential stratification, our study cohort was examined by <ext-link ext-link-type="uri" xlink:href="http://pritch.bsd.uchicago.edu/structure.html">Structure 2.0</ext-link> [27] using 26 unlinked genome-wide SNPs, as shown in our previous report [23]. </sec></sec></SecTag><SecTag type="RESULTS"><sec><title><text><SENT sid="8784" pm="."><plain>Results <p><text><SENT sid="8785" pm="."><plain>None of the SNPs reported in the present study showed any significant deviations from the Hardy–Weinberg equilibrium over the entire sample (p&gt;0.05). Table 2 summarizes the minor allelic frequencies for all SNPs and the results from a single-SNP association study. Significant differences in minor allelic frequencies were found in all SNPs tested between the tAMD and control subjects, as shown in our previous report [23], but there was no difference in minor allelic frequencies between the PCV and control subjects. Meanwhile, significant differences were found between PCV and tAMD patients at <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=3173798">rs3173798</ext-link> and <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=3173800">rs3173800</ext-link>. </plain></SENT>
<SENT sid="8788" pm="."><plain>The statistical powers of single-SNP association analysis at <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=3173798">rs3173798</ext-link> and <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=3173800">rs3173800</ext-link> were about 0.94 and 0.92, respectively (alpha error &lt;0.05), in the comparison between PCV and tAMD. The genotype association analysis revealed significant associations of <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=3173798">rs3173798</ext-link> and <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=3211883">rs3211883</ext-link> with tAMD, but not with PCV in the dominant model (Table 3). </plain></SENT>
<SENT sid="8790" pm="."><plain>In addition, the most significant differences were found between PCV and tAMD patients at <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=3173798">rs3173798</ext-link> and <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=3173800">rs3173800</ext-link> in the genotype (additive) model. In the haplotype analysis, the most frequent haplotype (T-T-T-T) at <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=10499862">rs10499862</ext-link>, <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=3173798">rs3173798</ext-link>, <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=3211883">rs3211883</ext-link>, and <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=3173800">rs3173800</ext-link> showed the most significant difference in association between PCV and tAMD (Table 4). </plain></SENT>
<SENT sid="8792" pm="."><plain>There was no evidence of significant stratification in our study cohort (Pr [K=1 &gt;0.99]). <SecTag type="TABLE"><table-wrap id="t2" position="float"><label>Table 2</label><caption><title><text><SENT sid="8793" pm="."><plain>Summary of single-SNP association analysis on gene CD36. </caption><table frame="hsides" rules="groups"><col width="67" span="1"/><col width="56" span="1"/><col width="49" span="1"/><col width="36" span="1"/><col width="43" span="1"/><col width="51" span="1"/><col width="70" span="1"/><col width="87" span="1"/><col width="95" span="1"/><thead><tr><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><text><SENT sid="8794" pm="."><plain>  </plain></SENT>
</text></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><text><SENT sid="8795" pm="."><plain>  </plain></SENT>
</text></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><text><SENT sid="8796" pm="."><plain>  </plain></SENT>
</text></th><th colspan="3" valign="top" align="center" scope="colgroup" rowspan="1"><text><SENT sid="8797" pm="."><plain>Minor allele frequency </plain></SENT>
</text></th><th colspan="3" valign="top" align="center" scope="colgroup" rowspan="1"><text><SENT sid="8798" pm="."><plain>Allelic nominal p-value (Bonferroni p-value) </plain></SENT>
</text></th></tr><tr><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><text><SENT sid="8799" pm="."><plain>SNP ID </plain></SENT>
</text></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><text><SENT sid="8800" pm="."><plain>Location </plain></SENT>
</text></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><text><SENT sid="8801" pm="."><plain>Major/ Minor </plain></SENT>
</text></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><text><SENT sid="8802" pm="."><plain>PCV </plain></SENT>
</text></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><text><SENT sid="8803" pm="."><plain>tAMD </plain></SENT>
</text></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><text><SENT sid="8804" pm="."><plain>Control </plain></SENT>
</text></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><text><SENT sid="8805" pm="."><plain>PCV versus control </plain></SENT>
</text></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><text><SENT sid="8806" pm="."><plain>tAMD versus control </plain></SENT>
</text></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><text><SENT sid="8807" pm="."><plain>PCV versus tAMD </plain></SENT>
</text></th></tr></thead><tbody><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1"><text><SENT sid="8808" pm="."><plain><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=10499862">rs10499862</ext-link> </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8809" pm="."><plain>Intron 3 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8810" pm="."><plain>T/C </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8811" pm="."><plain>0.14 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8812" pm="."><plain>0.11 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8813" pm="."><plain>0.18 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8814" pm="."><plain>0.058 (0.23) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8815" pm="."><plain>0.0066 (0.026) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8816" pm="."><plain>0.28 (1.0) </plain></SENT>
</text></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1"><text><SENT sid="8817" pm="."><plain><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=3173798">rs3173798</ext-link> </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8818" pm="."><plain>Intron 3 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8819" pm="."><plain>T/C </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8820" pm="."><plain>0.46 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8821" pm="."><plain>0.33 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8822" pm="."><plain>0.44 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8823" pm="."><plain>0.57 (1.0) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8824" pm="."><plain>0.005 (0.020) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8825" pm="."><plain>0.00081 (0.0032) </plain></SENT>
</text></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1"><text><SENT sid="8826" pm="."><plain><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=3211883">rs3211883</ext-link> </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8827" pm="."><plain>Intron 4 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8828" pm="."><plain>T/A </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8829" pm="."><plain>0.35 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8830" pm="."><plain>0.28 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8831" pm="."><plain>0.4 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8832" pm="."><plain>0.19 (0.76) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8833" pm="."><plain>0.0017 (0.0068) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8834" pm="."><plain>0.043 (0.17) </plain></SENT>
</text></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1"><text><SENT sid="8835" pm="."><plain><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=3173800">rs3173800</ext-link> </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8836" pm="."><plain>Intron 4 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8837" pm="."><plain>A/T </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8838" pm="."><plain>0.26 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8839" pm="."><plain>0.38 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8840" pm="."><plain>0.28 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8841" pm="."><plain>0.41 (1.0) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8842" pm="."><plain>0.0071 (0.028) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8843" pm="."><plain>0.0005 (0.0020) </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><p><text><SENT sid="8844" pm="."><plain>SNP: single nucleotide polymorphism, PCV: polypoidal choroidal vasculopathy, tAMD: typical neovascular AMD. </table-wrap-foot></table-wrap></SecTag><SecTag type="TABLE"><table-wrap id="t3" position="float"><label>Table 3</label><caption><title><text><SENT sid="8845" pm="."><plain>Summary of the genotype association analysis. </caption><table frame="hsides" rules="groups"><col width="67" span="1"/><col width="48" span="1"/><col width="68" span="1"/><col width="68" span="1"/><col width="65" span="1"/><col width="113" span="1"/><col width="55" span="1"/><col width="93" span="1"/><col width="57" span="1"/><col width="57" span="1"/><col width="68" span="1"/><thead><tr><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><text><SENT sid="8846" pm="."><plain>  </plain></SENT>
</text></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><text><SENT sid="8847" pm="."><plain>  </plain></SENT>
</text></th><th colspan="3" valign="top" align="center" scope="colgroup" rowspan="1"><text><SENT sid="8848" pm="."><plain>Genotype frequency (%) </plain></SENT>
</text></th><th colspan="6" valign="top" align="center" scope="colgroup" rowspan="1"><text><SENT sid="8849" pm="."><plain>Genotype association results </plain></SENT>
</text></th></tr><tr><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><text><SENT sid="8850" pm="."><plain>  </plain></SENT>
</text></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><text><SENT sid="8851" pm="."><plain>  </plain></SENT>
</text></th><th colspan="3" valign="top" align="center" scope="colgroup" rowspan="1"><text><SENT sid="8852" pm="."><plain>Genotype (Major homo/Hetero/Minor homo) </plain></SENT>
</text></th><th colspan="2" valign="top" align="center" scope="colgroup" rowspan="1"><text><SENT sid="8853" pm="."><plain>PCV versus Control (dominant model) </plain></SENT>
</text></th><th colspan="2" valign="top" align="center" scope="colgroup" rowspan="1"><text><SENT sid="8854" pm="."><plain>tAMD versus Control (dominant model) </plain></SENT>
</text></th><th colspan="2" valign="top" align="center" scope="colgroup" rowspan="1"><text><SENT sid="8855" pm="."><plain>PCV versus tAMD (genotype model) </plain></SENT>
</text></th></tr><tr><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><text><SENT sid="8856" pm="."><plain>SNP ID </plain></SENT>
</text></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><text><SENT sid="8857" pm="."><plain>Major/ Minor </plain></SENT>
</text></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><text><SENT sid="8858" pm="."><plain>PCV </plain></SENT>
</text></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><text><SENT sid="8859" pm="."><plain>tAMD </plain></SENT>
</text></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><text><SENT sid="8860" pm="."><plain>Control </plain></SENT>
</text></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><text><SENT sid="8861" pm="."><plain>OR (95%CI) </plain></SENT>
</text></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><text><SENT sid="8862" pm="."><plain>Nominal p value </plain></SENT>
</text></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><text><SENT sid="8863" pm="."><plain>OR (95%CI) </plain></SENT>
</text></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><text><SENT sid="8864" pm="."><plain>Nominal p value </plain></SENT>
</text></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><text><SENT sid="8865" pm="."><plain>Nominal p value </plain></SENT>
</text></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><text><SENT sid="8866" pm="."><plain>Corrected p value* </plain></SENT>
</text></th></tr></thead><tbody><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1"><text><SENT sid="8867" pm="."><plain><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=10499862">rs10499862</ext-link> </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8868" pm="."><plain>T/C </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8869" pm="."><plain>75/22/3 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8870" pm="."><plain>81/17/2 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8871" pm="."><plain>67/29/4 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8872" pm="."><plain>0.58 (0.19–1.80) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8873" pm="."><plain>0.34 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8874" pm="."><plain>0.52 (0.14–2.01) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8875" pm="."><plain>0.34 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8876" pm="."><plain>0.5 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8877" pm="."><plain>0.52 </plain></SENT>
</text></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1"><text><SENT sid="8878" pm="."><plain><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=3173798">rs3173798</ext-link> </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8879" pm="."><plain>T/C </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8880" pm="."><plain>28/51/21 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8881" pm="."><plain>45/44/11 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8882" pm="."><plain>36/40/24 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8883" pm="."><plain>0.8 (0.50–1.28) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8884" pm="."><plain>0.36 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8885" pm="."><plain>0.41 (0.22–0.75) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8886" pm="."><plain>0.0034 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8887" pm="."><plain>0.0031 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8888" pm="."><plain>0.0033 </plain></SENT>
</text></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1"><text><SENT sid="8889" pm="."><plain><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=3211883">rs3211883</ext-link> </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8890" pm="."><plain>T/A </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8891" pm="."><plain>42/45/13 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8892" pm="."><plain>52/40/8 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8893" pm="."><plain>40/41/19 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8894" pm="."><plain>0.59 (0.35–1.02) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8895" pm="."><plain>0.059 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8896" pm="."><plain>0.36 (0.18–0.74) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8897" pm="."><plain>0.0038 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8898" pm="."><plain>0.13 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8899" pm="."><plain>0.14 </plain></SENT>
</text></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1"><text><SENT sid="8900" pm="."><plain><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=3173800">rs3173800</ext-link> </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8901" pm="."><plain>A/T </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8902" pm="."><plain>52/44/4 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8903" pm="."><plain>37/50/13 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8904" pm="."><plain>54/36/10 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8905" pm="."><plain>0.35 (0.15–0.82) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8906" pm="."><plain>0.012 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8907" pm="."><plain>1.32 (0.67–2.61) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8908" pm="."><plain>0.42 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8909" pm="."><plain>0.00067 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8910" pm="."><plain>0.00069 </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><p><text><SENT sid="8911" pm="."><plain>Corrections were performed with permutation test. SNP: single nucleotide polymorphism, PCV: polypoidal choroidal vasculopathy, tAMD: typical neovascular AMD, OR: odds ratio, CI: coefficient interval. </table-wrap-foot></table-wrap></SecTag><SecTag type="TABLE"><table-wrap id="t4" position="float"><label>Table 4</label><caption><title><text><SENT sid="8913" pm="."><plain>Haplotype-based association study. </caption><table frame="hsides" rules="groups"><col width="47" span="1"/><col width="64" span="1"/><col width="49" span="1"/><col width="40" span="1"/><col width="43" span="1"/><col width="52" span="1"/><col width="51" span="1"/><col width="49" span="1"/><col width="45" span="1"/><thead><tr><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><text><SENT sid="8914" pm="."><plain>  </plain></SENT>
</text></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><text><SENT sid="8915" pm="."><plain>  </plain></SENT>
</text></th><th colspan="4" valign="top" align="center" scope="colgroup" rowspan="1"><text><SENT sid="8916" pm="."><plain>Frequency </plain></SENT>
</text></th><th colspan="3" valign="top" align="center" scope="colgroup" rowspan="1"><text><SENT sid="8917" pm="."><plain>Permutation P </plain></SENT>
</text></th></tr><tr><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><text><SENT sid="8918" pm="."><plain>Index </plain></SENT>
</text></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><text><SENT sid="8919" pm="."><plain>Haplotype </plain></SENT>
</text></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><text><SENT sid="8920" pm="."><plain>Overall </plain></SENT>
</text></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><text><SENT sid="8921" pm="."><plain>PCV </plain></SENT>
</text></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><text><SENT sid="8922" pm="."><plain>tAMD </plain></SENT>
</text></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><text><SENT sid="8923" pm="."><plain>Control </plain></SENT>
</text></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><text><SENT sid="8924" pm="."><plain>PCV versus control </plain></SENT>
</text></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><text><SENT sid="8925" pm="."><plain>tAMD versus control </plain></SENT>
</text></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><text><SENT sid="8926" pm="."><plain>PCV versus tAMD </plain></SENT>
</text></th></tr></thead><tbody><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1"><text><SENT sid="8927" pm="."><plain>H1 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8928" pm="."><plain>T-T-T-T </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8929" pm="."><plain>0.32 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8930" pm="."><plain>0.26 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8931" pm="."><plain>0.38 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8932" pm="."><plain>0.28 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8933" pm="."><plain>0.45 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8934" pm="."><plain>0.01 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8935" pm="."><plain>0.001 </plain></SENT>
</text></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1"><text><SENT sid="8936" pm="."><plain>H2 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8937" pm="."><plain>T-T-T-A </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8938" pm="."><plain>0.28 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8939" pm="."><plain>0.28 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8940" pm="."><plain>0.28 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8941" pm="."><plain>0.27 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8942" pm="."><plain>0.82 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8943" pm="."><plain>0.8 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8944" pm="."><plain>0.97 </plain></SENT>
</text></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1"><text><SENT sid="8945" pm="."><plain>H3 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8946" pm="."><plain>T-C-A-A </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8947" pm="."><plain>0.19 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8948" pm="."><plain>0.21 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8949" pm="."><plain>0.17 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8950" pm="."><plain>0.21 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8951" pm="."><plain>0.85 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8952" pm="."><plain>0.27 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8953" pm="."><plain>0.2 </plain></SENT>
</text></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1"><text><SENT sid="8954" pm="."><plain>H4 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8955" pm="."><plain>C-C-A-A </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8956" pm="."><plain>0.15 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8957" pm="."><plain>0.14 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8958" pm="."><plain>0.11 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8959" pm="."><plain>0.19 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8960" pm="."><plain>0.06 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8961" pm="."><plain>0.005 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8962" pm="."><plain>0.25 </plain></SENT>
</text></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1"><text><SENT sid="8963" pm="."><plain>H5 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8964" pm="."><plain>T-C-T-A </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8965" pm="."><plain>0.05 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8966" pm="."><plain>0.11 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8967" pm="."><plain>0.06 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8968" pm="."><plain>0.05 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8969" pm="."><plain>0.001 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8970" pm="."><plain>0.63 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="8971" pm="."><plain>0.018 </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><p><text><SENT sid="8972" pm="."><plain>Selected SNPs are <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=10499862">rs10499862</ext-link>/<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=3173798">rs3173798</ext-link>/<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=3211883">rs3211883</ext-link>/<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=3173800">rs3173800</ext-link>. </plain></SENT>
<SENT sid="8973" pm="."><plain>SNP: single nucleotide polymorphism, PCV: polypoidal choroidal vasculopathy, tAMD: typical neovascular AMD. </table-wrap-foot></table-wrap></SecTag></sec></SecTag><SecTag type="DISCUSS"><sec><title><text><SENT sid="8974" pm="."><plain>Discussion <p><text><SENT sid="8975" pm="."><plain>We genotyped four tag SNPs in the CD36 region, and found that the minor allelic frequencies at SNPs <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=3173798">rs3173798</ext-link> and <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=3173800">rs3173800</ext-link> and the haplotype at four selected SNPs in the CD36 region were significantly associated with the difference in genetic susceptibility to PCV and tAMD. Namely, T, T alleles were less frequent than C, A alleles in PCV than in tAMD patients at <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=3173798">rs3173798</ext-link> and <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=3173800">rs3173800</ext-link>, respectively. Moreover, the T-T-T-T haplotype at <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=10499862">rs10499862</ext-link>, <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=3173798">rs3173798</ext-link>, <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=3211883">rs3211883</ext-link>, and <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=3173800">rs3173800</ext-link> on introns 3 and 4 in the CD36 region was significantly less frequent in PCV than in tAMD. <p><text><SENT sid="8978" pm="."><plain>Although our previous report demonstrated an association of SNPs in the CD36 region with neovascular AMD [23], the phenotype specificity of these SNPs remained to be elucidated. The present study suggests a different association of CD36 in genetic susceptibility for PCV and tAMD, which may contribute to the different clinical characteristics of PCV (i.e., natural course and the response to PDT or ranibizumab) from tAMD [3,4,6-9]. </plain></SENT>
<SENT sid="8980" pm="."><plain>Since the SNPs at <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=10499862">rs10499862</ext-link>, <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=3173798">rs3173798</ext-link>, <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=3211883">rs3211883</ext-link>, and <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=3173800">rs3173800</ext-link> were not covered by the gene chips used in previous genome-wide association studies [28,29], they could not be detected as possible causative SNPs for AMD in those studies. The present study, as well as our previous report [23], further suggested an association of this region in CD36 with the incidence of tAMD. However, these SNPs did not remain significant in the prevalence of PCV. Moreover, a statistically significant difference was detected in the association of this region between tAMD and PCV. This suggests a different association of the CD36 region with the phenotype of neovascular AMD, although the details have not yet been clarified. A recent in vivo study demonstrated that a downregulation of CD36 in capillary sprout endothelial cells facilitated angiogenesis [30]. </plain></SENT>
<SENT sid="8986" pm="."><plain>Rats carrying a specific genetic variant of CD36 have been found to be more susceptible to light-induced retinal damage, and are more likely to develop age-related retinal degeneration and choriocapillary rarefaction [31]. </plain></SENT>
<SENT sid="8987" pm="."><plain>CD36 is involved in diverse physiologic and pathological processes, including scavenger receptor functions, transforming growth factor-β activation, lipid metabolism, angiogenesis, atherogenesis, and inflammation, depending on the ligands with which CD36 can interact [20-22]. </plain></SENT>
<SENT sid="8988" pm="."><plain>In particular, the scavenging ability of CD36 for oxidative stress is critical to manage AMD, since oxidative stress is widely recognized as an important component in the pathogenesis of AMD [32,33] and in the mechanism whereby PDT works to occlude neovascular tracts [34]. </plain></SENT>
<SENT sid="8989" pm="."><plain>A recent in vitro study reported that the uptake of oxidized low-density lipoprotein (oxLDL) induces the expression of several genes related to oxidative stress, inflammation, and apoptosis in retinal pigment epithelium cells [35]. </plain></SENT>
<SENT sid="8990" pm="."><plain>An immunohistochemical study reported the presence of oxLDL in surgically excised choroidal neovascularization membranes [36]. </plain></SENT>
<SENT sid="8991" pm="."><plain>Moreover, the verteporfin used in PDT binds with serum LDL, and this complex is incorporated into choroidal neovascularization tissues [37]. </plain></SENT>
<SENT sid="8992" pm="."><plain>Although it is not known whether lipid metabolism and oxidative stress play different roles in the pathogenesis between tAMD and PCV, the present study implied different genetic susceptibilities for each AMD phenotype. Interestingly, recent reports demonstrated a difference between tAMD and PCV in their histological findings and systemic risk factors [38,39]. </plain></SENT>
<SENT sid="8994" pm="."><plain>Moreover, our previous study demonstrated a different association of an elastin gene polymorphism with tAMD and PCV [13]. <p><text><SENT sid="8995" pm="."><plain>The biologic basis of the association with the haplotype in CD36 is currently unknown, because the haplotype in the present study does not reside in the coding sequence of CD36. </plain></SENT>
<SENT sid="8996" pm="."><plain>FASTSNP [40] gave the information that <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=3173798">rs3173798</ext-link> is located at splicing site with medium-high effect, but it was not shown whether it is located at splice donor site or acceptor site [41]. </plain></SENT>
<SENT sid="8997" pm="."><plain>Thus, the SNPs in this region could have noncoding effects on gene expression and function. A recent study demonstrated that the C allele at <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=3173798">rs3173798</ext-link> tended to increase CD36 expression while reducing high-density lipoprotein levels [41,42]. </plain></SENT>
<SENT sid="8999" pm="."><plain>Since the C allele at <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=3173798">rs3173798</ext-link> was less frequent in the tAMD group than the PCV and control groups, the reduced expression of CD36 might be correlated with tAMD but not PCV pathogenesis. Moreover, Picard et al. have recently demonstrated an accumulation of oxLDL in Bruch’s membrane among aged CD36 knockout mice [43]. </plain></SENT>
<SENT sid="9001" pm="."><plain>The oxLDL accelerates an accumulation of deposits in Bruch’s membrane and causes drusen. Interestingly, drusens are more frequently seen in tAMD than PCV [44]. </plain></SENT>
<SENT sid="9003" pm="."><plain>However, exhaustive resequencing of this locus may elucidate potentially undiscovered and more important causative variants. In addition, it is essential to perform replication studies using other cohorts to verify and conclude the associations of CD36 variants with tAMD and PCV. <p><text><SENT sid="9005" pm="."><plain>The limitation of this study was a possible influence of lipid metabolism on AMD pathogenesis [45,46]. </plain></SENT>
<SENT sid="9006" pm="."><plain>Since CD36 is known to associate with the metabolic syndrome and hyperlipidemia [41,47], CD36 variants may indirectly contribute to AMD via abnormal lipid metabolism. However, the results of this study suggest a possible role of lipid metabolism in the different pathogeneses between PCV and tAMD. <p><text><SENT sid="9008" pm="."><plain>In conclusion, the present study suggested some clinical possibilities for genetic association analysis that can be further investigated to determine the specific pathogenesis of PCV as distinct from that of tAMD. </sec></SecTag></body><back><SecTag type="ACK_FUND"><ack><title>Acknowledgments</title><p><text4fund><text><SENT sid="9009" pm="."><plain>This study was supported by a Grant-in Aid (C) 23592567 from the Ministry of Education, Science and Culture, Tokyo, Japan (S.H.), and by a grant from the Takeda Science Foundation, Osaka, Japan (S.H.). </plain></SENT>
<SENT sid="9010" pm="."><plain>The funding organization had no role in the design or conduct of this research. The authors have no proprietary or commercial interest in any of the materials discussed in this article. </p></ack></SecTag><SecTag type="REF"><ref-list><title>References</title><ref id="r1"><text><SENT sid="9012" pm="."><plain>1CongdonNO'ColmainBKlaverCCKleinRMuñozBFriedmanDSKempenJTaylorHRMitchellPEye Diseases Prevalence Research GroupCauses and prevalence of visual impairment among adults the United States.Arch Ophthalmol20041224778515078664 </plain></SENT>
</text></ref><ref id="r2"><text><SENT sid="9013" pm="."><plain>2ReinDBWittenbornJSZhangXHoneycuttAALesesneSBSaaddineJVision Health Cost-Effectiveness Study GroupForecasting age-related macular degeneration through the year 2050: the potential impact of new treatments.Arch Ophthalmol20091275334019365036 </plain></SENT>
</text></ref><ref id="r3"><text><SENT sid="9014" pm="."><plain>3YannuzziLASorensonJSpaideRFLipsonBIdiopathic polypoidal choroidal vasculopathy (IPCV).Retina199010181693009 </plain></SENT>
</text></ref><ref id="r4"><text><SENT sid="9015" pm="."><plain>4KleinerRCBruckerAJJohnstonRLThe posterior uveal bleeding syndrome.Retina1990109172343198 </plain></SENT>
</text></ref><ref id="r5"><text><SENT sid="9016" pm="."><plain>5YannuzziLANegraoSIidaTCarvalhoCRodriguez-ColemanHSlakterJFreundKBSorensonJOrlockDBorodokerNRetinal angiomatous proliferation in age-related macular degeneration.Retina2001214163411642370 </plain></SENT>
</text></ref><ref id="r6"><text><SENT sid="9017" pm="."><plain>6BesshoHHondaSImaiHNegiANatural course and funduscopic findings of polypoidal choroidal vasculopathy in a Japanese population over 1 year of follow-up.Retina201131159860221478804 </plain></SENT>
</text></ref><ref id="r7"><text><SENT sid="9018" pm="."><plain>7HondaSKurimotoYKagotaniYYamamotoHTakagiHUenishiMHyogo Macular Disease Study GroupPhotodynamic therapy for typical age-related macular degeneration and polypoidal choroidal vasculopathy: a 30-month multicenter study in Hyogo, Japan.Jpn J Ophthalmol200953593720020237 </plain></SENT>
</text></ref><ref id="r8"><text><SENT sid="9019" pm="."><plain>8HondaSImaiHYamashiroKKurimotoYKanamori-MatsuiNKagotaniYTamuraYYamamotoHOhotoSTakagiHUenishiMNegiAComparative assessment of photodynamic therapy for typical age-related macular degeneration and polypoidal choroidal vasculopathy: a multicenter study in Hyogo prefecture, Japan.Ophthalmologica2009223333819478533 </plain></SENT>
</text></ref><ref id="r9"><text><SENT sid="9020" pm="."><plain>9LimJYLeeSYKimJGLeeJYChungHYoonYHIntravitreal bevacizumab alone versus in combination with photodynamic therapy for the treatment of neovascular maculopathy in patients aged 50 years or older: 1-year results of a prospective clinical study. Acta Ophthalmol 2010 20337606 </plain></SENT>
</text></ref><ref id="r10"><text><SENT sid="9021" pm="."><plain>10MatsumiyaWHondaSBesshoHKusuharaSTsukaharaYNegiAEarly responses to intravitreal ranibizumab in typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.J Ophthalmol2011201174202021772985 </plain></SENT>
</text></ref><ref id="r11"><text><SENT sid="9022" pm="."><plain>11BesshoHHondaSKondoNNegiAThe association of ARMS2 polymorphisms with phenotype in typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.Mol Vis2011179778221541271 </plain></SENT>
</text></ref><ref id="r12"><text><SENT sid="9023" pm="."><plain>12BesshoHHondaSKondoNNishimuraKNegiAPositive association of complement factor H gene variants with the effect of photodynamic therapy in polypoidal choroidal vasculopathy.J Clinic Experiment Ophthalmol.20112122 </plain></SENT>
</text></ref><ref id="r13"><text><SENT sid="9024" pm="."><plain>13KondoNHondaSIshibashiKTsukaharaYNegiAElastin gene polymorphisms in neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.Invest Ophthalmol Vis Sci2008491101518326737 </plain></SENT>
</text></ref><ref id="r14"><text><SENT sid="9025" pm="."><plain>14ChowersIMeirTLedermanMGoldenberg-CohenNCohenYBaninEAverbukhEHemoIPollackAAxer-SiegelRWeinsteinOHohJZackDJGalbinurTSequence variants in HTRA1 and LOC387715/ARMS2 and phenotype and response to photodynamic therapy in neovascular age-related macular degeneration in populations from Israel.Mol Vis20081422637119065273 </plain></SENT>
</text></ref><ref id="r15"><text><SENT sid="9026" pm="."><plain>15BrantleyMAJrEdelsteinSLKingJMPlotzkeMRApteRSKymesSMShielsAAssociation of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to photodynamic therapy.Eye (Lond)2009236263118292785 </plain></SENT>
</text></ref><ref id="r16"><text><SENT sid="9027" pm="."><plain>16GotohNYamadaRNakanishiHSaitoMIidaTMatsudaFYoshimuraNCorrelation between CFH Y402H and HTRA1 rs11200638 genotype to typical exudative age-related macular degeneration and polypoidal choroidal vasculopathy phenotype in the Japanese population.Clin Experiment Ophthalmol2008364374218939352 </plain></SENT>
</text></ref><ref id="r17"><text><SENT sid="9028" pm="."><plain>17SakuradaYKubotaTImasawaMTsumuraTMabuchiFTanabeNIijimaHAngiographic lesion size associated with LOC387715 A69S genotype in subfoveal polypoidal choroidal vasculopathy.Retina2009291522619898184 </plain></SENT>
</text></ref><ref id="r18"><text><SENT sid="9029" pm="."><plain>18MoriKHorie-InoueKGehlbachPLTakitaHKabasawaSKawasakiIOhkuboTKuriharaSIizukaHMiyashitaYKatayamaSAwataTYoneyaSInoueSPhenotype and genotype characteristics of age-related macular degeneration in a Japanese population.Ophthalmology20101179283820132989 </plain></SENT>
</text></ref><ref id="r19"><text><SENT sid="9030" pm="."><plain>19TsuchihashiTMoriKHorie-InoueKGehlbachPLKabasawaSTakitaHUeyamaKOkazakiYInoueSAwataTKatayamaSYoneyaSComplement factor H and high-temperature requirement A-1 genotypes and treatment response of age-related macular degeneration.Ophthalmology20111189310020678803 </plain></SENT>
</text></ref><ref id="r20"><text><SENT sid="9031" pm="."><plain>20SilversteinRLFebbraioMCD36 and atherosclerosis.Curr Opin Lipidol2000114839111048891 </plain></SENT>
</text></ref><ref id="r21"><text><SENT sid="9032" pm="."><plain>21FebbraioMHajjarDPSilversteinRLCD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism.J Clin Invest20011087859111560944 </plain></SENT>
</text></ref><ref id="r22"><text><SENT sid="9033" pm="."><plain>22KuniyasuAOhgamiNHayashiSMiyazakiAHoriuchiSNakayamaHCD36-mediated endocytic uptake of advanced glycation end products (AGE) in mouse 3T3–L1 and human subcutaneous adipocytes.FEBS Lett2003537859012606036 </plain></SENT>
</text></ref><ref id="r23"><text><SENT sid="9034" pm="."><plain>23KondoNHondaSKunoSNegiAPositive Association of Common Variants in CD36 with Neovascular Age-Related Macular Degeneration.Aging200912667420157514 </plain></SENT>
</text></ref><ref id="r24"><text><SENT sid="9035" pm="."><plain>24YamashiroKMoriKNakataITsuchihashiTHorie-InoueKNakanishiHTsujikawaASaitoMIidaTYamadaRMatsudaFInoueSAwataTYoneyaSYoshimuraNAssociation of elastin gene polymorphism to age-related macular degeneration and polypoidal choroidal vasculopathy.Invest Ophthalmol Vis Sci2011528780422003121 </plain></SENT>
</text></ref><ref id="r25"><text><SENT sid="9036" pm="."><plain>25TanakaKNakayamaTYuzawaMWangZKawamuraAMoriRNakashizukaHSatoNMizutaniYAnalysis of candidate genes for age-related macular degeneration subtypes in the Japanese population.Mol Vis2011172751822065928 </plain></SENT>
</text></ref><ref id="r26"><text><SENT sid="9037" pm="."><plain>26Japanese Study Group of Polypoidal Choroidal VasculopathyCriteria for diagnosis of polypoidal choroidal vasculopathyNippon Ganka Gakkai Zasshi20051094172716050460 </plain></SENT>
</text></ref><ref id="r27"><text><SENT sid="9038" pm="."><plain>27FalushDStephensMPritchardJKInference of population structure using multilocus genotype data: linked loci and correlated allele frequencies.Genetics200316415678712930761 </plain></SENT>
</text></ref><ref id="r28"><text><SENT sid="9039" pm="."><plain>28NealeBMFagernessJReynoldsRSobrinLParkerMRaychaudhuriSTanPLOhECMerriamJESouiedEBernsteinPSLiBFrederickJMZhangKBrantleyMAJrLeeAYZackDJCampochiaroBCampochiaroPRipkeSSmithRTBarileGRKatsanisNAllikmetsRDalyMJSeddonJMGenome-wide association study of advanced age-related macular degeneration identifies a role of the hepatic lipase gene (LIPC).Proc Natl Acad Sci USA2010107739540020385826 </plain></SENT>
</text></ref><ref id="r29"><text><SENT sid="9040" pm="."><plain>29ChenWStambolianDEdwardsAOBranhamKEOthmanMJakobsdottirJTosakulwongNPericak-VanceMACampochiaroPAKleinMLTanPLConleyYPKandaAKopplinLLiYAugustaitisKJKaroukisAJScottWKAgarwalAKovachJLSchwartzSGPostelEABrooksMBaratzKHBrownWLBruckerAJOrlinABrownGHoARegilloCDonosoLTianLKaderliBHadleyDHagstromSAPeacheyNSKleinRKleinBEGotohNYamashiroKFerris IiiFFagernessJAReynoldsRFarrerLAKimIKMillerJWCortónMCarracedoASanchez-SalorioMPughEWDohenyKFBrionMDeangelisMMWeeksDEZackDJChewEYHeckenlivelyJRYoshimuraNIyengarSKFrancisPJKatsanisNSeddonJMHainesJLGorinMBAbecasisGRSwaroopAGenetic variants near TIMP3 and high-density lipoprotein-associated loci influence susceptibility to age-related macular degeneration.Proc Natl Acad Sci USA20101077401620385819 </plain></SENT>
</text></ref><ref id="r30"><text><SENT sid="9041" pm="."><plain>30AndersonCRHastingsNEBlackmanBRPriceRJCapillary sprout endothelial cells exhibit a CD36low phenotype. Regulation by shear stress and vascular endothelial growth factor-induced mechanism for attenuating anti-proliferative thrombospondin-1 signaling.Am J Pathol20081731220818772338 </plain></SENT>
</text></ref><ref id="r31"><text><SENT sid="9043" pm="."><plain>31HoussierMRaoulWLavaletteSKellerNGuillonneauXBaragattiBJonetLJeannyJCBehar-CohenFCoceaniFSchermanDLachapellePOngHChemtobSSennlaubFCD36 deficiency leads to choroidal involution via COX2 down-regulation in rodents.PLoS Med20085e3918288886 </plain></SENT>
</text></ref><ref id="r32"><text><SENT sid="9044" pm="."><plain>32ZarbinMACurrent concepts in the pathogenesis of age-related macular degeneration.Arch Ophthalmol200412259861415078679 </plain></SENT>
</text></ref><ref id="r33"><text><SENT sid="9045" pm="."><plain>33BeattySKohHPhilMHensonDBoultonMThe role of oxidative stress in the pathogenesis of age-related macular degeneration.Surv Ophthalmol2000451153411033038 </plain></SENT>
</text></ref><ref id="r34"><text><SENT sid="9046" pm="."><plain>34van den BerghHPhotodynamic therapy of age-related macular degeneration: History and principles.Semin Ophthalmol20011618120015513440 </plain></SENT>
</text></ref><ref id="r35"><text><SENT sid="9047" pm="."><plain>35YamadaYTianJYangYCutlerRGWuTTelljohannRSMattsonMPHandaJTOxidized low density lipoproteins induce a pathologic response by retinal pigmented epithelial cells.J Neurochem200810511879718182060 </plain></SENT>
</text></ref><ref id="r36"><text><SENT sid="9048" pm="."><plain>36KameiMYonedaKKumeNSuzukiMItabeHMatsudaKShimaokaTMinamiMYoneharaSKitaTKinoshitaSScavenger receptors for oxidized lipoprotein in age-related macular degeneration.Invest Ophthalmol Vis Sci2007481801717389514 </plain></SENT>
</text></ref><ref id="r37"><text><SENT sid="9049" pm="."><plain>37ScottLJGoaKLVerteporfin.Drugs Aging20001613946, discussion 147–8.10755329 </plain></SENT>
</text></ref><ref id="r38"><text><SENT sid="9050" pm="."><plain>38NakashizukaHMitsumataMOkisakaSShimadaHKawamuraAMoriRYuzawaMClinicopathologic findings in polypoidal choroidal vasculopathy.Invest Ophthalmol Vis Sci20084947293718586873 </plain></SENT>
</text></ref><ref id="r39"><text><SENT sid="9051" pm="."><plain>39UetaTObataRInoueYIriyamaATakahashiHYamaguchiTTamakiYYanagiYBackground comparison of typical age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese patients.Ophthalmology20091162400619815291 </plain></SENT>
</text></ref><ref id="r40"><text><SENT sid="9052" pm="."><plain>40YuanHYChiouJJTsengWHLiuCHLiuCKLinYJWangHHYaoAChenYTHsuCNFASTSNP: an always up-to-date and extendable service for SNP function analysis and prioritization.Nucleic Acids Res200634W635–4116845089 </plain></SENT>
</text></ref><ref id="r41"><text><SENT sid="9053" pm="."><plain>41Love-GregoryLShervaRSunLWassonJSchappeTDoriaARaoDCHuntSCKleinSNeumanRJPermuttMAAbumradNAVariants in the CD36 gene associate with the metabolic syndrome and high-density lipoprotein cholesterol.Hum Mol Genet200817169570418305138 </plain></SENT>
</text></ref><ref id="r42"><text><SENT sid="9054" pm="."><plain>42Love-GregoryLShervaRSchappeTQiJSMcCreaJKleinSConnellyMAAbumradNACommon CD36 SNPs reduce protein expression and may contribute to a protective atherogenic profile.Hum Mol Genet20112019320120935172 </plain></SENT>
</text></ref><ref id="r43"><text><SENT sid="9055" pm="."><plain>43PicardEHoussierMBujoldKQiJSMcCreaJKleinSConnellyMAAbumradNACD36 plays an important role in the clearance of oxLDL and associated age-dependent sub-retinal deposits.Aging (Albany NY)20102981921098885 </plain></SENT>
</text></ref><ref id="r44"><text><SENT sid="9056" pm="."><plain>44LaudeACackettPDVithanaENYeoIYWongDKohAHWongTYAungTPolypoidal choroidal vasculopathy and neovascular age-related macular degeneration: same or different disease?Prog Retin Eye Res201029192919854291 </plain></SENT>
</text></ref><ref id="r45"><text><SENT sid="9057" pm="."><plain>45KishanAUModjtahediBSMartinsENModjtahediSPMorseLSLipids and age-related macular degeneration.Surv Ophthalmol20115619521321439604 </plain></SENT>
</text></ref><ref id="r46"><text><SENT sid="9058" pm="."><plain>46StahlAKrohneTUSapiehaPChenJHellstromAChewEHolzFGSmithLELipid metabolites in the pathogenesis and treatment of neovascular eye disease.Br J Ophthalmol201195149650121421650 </plain></SENT>
</text></ref><ref id="r47"><text><SENT sid="9059" pm="."><plain>47SilversteinRLType 2 scavenger receptor CD36 in platelet activation: the role of hyperlipemia and oxidative stress.Clin Lipidol.2009476720161667 </plain></SENT>
</text></ref></ref-list></SecTag></back></article>
